Antoniou and colleagues1 reported that dabigatran etexilate was associated with increased
major hemorrhage risk, when coadministered with simvastatin or lovastatin, relative to other …

BACKGROUND: Dabigatran etexilate is a prodrug whose absorption is opposed by
intestinal P-glycoprotein and which is converted by carboxylesterase to its active form …

Objectives Dabigatran etexilate is a direct thrombin inhibitor that clinicians increasingly
prescribe to prevent stroke in patients with non‐valvular atrial fibrillation (NVAF). Clinicians …

Background Dabigatran etexilate, a novel oral direct thrombin inhibitor, has been approved
for prophylaxis of thromboembolism in patients undergoing total knee or total hip …

PURPOSE: Recent observations in patients with atrial fibrillation who are receiving warfarin
suggest that concomitant treatment with a 3-hydroxy-3-methylglutaryl coenzyme A reductase …

Higher risk of major hemorrhage associated with concomitant use of dabigatran and
simvastatin compared to other statins was previously reported with a suggestion of P …

Background: Experimental and clinical studies suggest that statins may have direct
anticoagulant and antiplatelet properties unrelated to their lipid-lowering effect. The goal of …

This week we put the spotlight on two drug blockbusters at the heart of one of the major
issues The BMJ has campaigned on in recent years: transparency, the focus of our Open …

Clinical significance of potential interaction between warfarin and statins is unclear. Our
objective was to determine whether use of statins as a class or use of simvastatin modulates …

Background Statins are frequently prescribed with direct oral anticoagulants (DOACs), and
previous studies have raised concerns about the increased risk of intracerebral hemorrhage …